Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder

Andrew W. Goddard, Anantha Shekhar, Aaron F. Whiteman, Christopher J. McDougle

Research output: Contribution to journalReview article

72 Scopus citations

Abstract

Obsessive-compulsive disorder (OCD) is a disabling psychiatric condition affecting 1-2% of the community. Although modern drug, behavioral and psychosurgical therapies have improved the prognosis of OCD considerably, approximately 30% of patients remain treatment-refractory. Currently, selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the drug treatments of choice for OCD. Accordingly, this review evaluates the evidence for a role of the serotonin (5-HT) neurochemical system in the treatment and pathophysiology of OCD. However, drug treatment approaches that modify function of interrelated neurochemical systems, such as the dopamine and glutamate systems, are also briefly discussed as they promise to complement and enhance SSRI treatment effects.

Original languageEnglish (US)
Pages (from-to)325-332
Number of pages8
JournalDrug Discovery Today
Volume13
Issue number7-8
DOIs
StatePublished - Apr 1 2008

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder'. Together they form a unique fingerprint.

  • Cite this